✦ LIBER ✦

Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma

✍ Scribed by Ghadiany, Mojtaba; Foratyazdi, Mohammad; Rahimi, Hossein; Rezvani, Hamid; Sadeghi, Lila; Fathali, Abbas Haji

Book ID: 120959616
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 188 KB
Volume: 30
Category: Article
ISSN: 0971-4502
DOI: 10.1007/s12288-013-0269-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Irinotecan plus cisplatin and dexamethas

Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP

✍ Hye Jin Kang; Won Seog Kim; Cheolwon Suh; Yeon Hee Park; Bong Seog Kim; Young Ji 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 242 KB

Bortezomib in combination with rituximab

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

✍ Elstrom, Rebecca L.; Andemariam, Biree; Martin, Peter; Ruan, Jia; Shore, Tsipora 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 224 KB

Outcomes of salvage chemotherapy and aut

Outcomes of salvage chemotherapy and autologous transplantation for large cell transformation of follicular lymphoma—A comparison of outcomes with relapsed/refractory diffuse large B cell lymphoma

✍ J. Kuruvilla; C. Chen; M. Pintilie; T. Nagy; A. Keating; M. Crump 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

The role of ifosfamide plus cisplatin-ba

The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors

✍ Robert J. Motzer; Karen Cooper; Nancy L. Geller; Dean F. Bajorin; Ethan Dmitrovs 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 537 KB

A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy. Forty patients were evaluable for response. Ten patients (25%) had a complete